Moreover, genomic analyses of large sequencing cohorts comparing metastatic versus primary disease revealed TP53 mutations were significantly enriched in metastatic disease, and this was particularly robust in PCa [1, 2]. Here, TP53 is linked to metastatic neoplasm.